Antimicrobial Agents — MCQs

Antimicrobial Agents Indian Medical PG Practice Questions and MCQs

Question 461: Which of the following is NOT a true statement regarding the mechanism of action of the listed antimicrobial agents?

A. Chloramphenicol inhibits protein synthesis.
B. Tetracycline inhibits cell wall synthesis. (Correct Answer)
C. Metronidazole damages DNA.
D. Penicillin inhibits cell wall synthesis.

Explanation: ### Explanation The correct answer is **B. Tetracycline inhibits cell wall synthesis.** This statement is false because Tetracyclines are **protein synthesis inhibitors**, not cell wall synthesis inhibitors. #### 1. Why Option B is the Correct Choice (The False Statement) Tetracyclines (e.g., Doxycycline, Minocycline) act by reversibly binding to the **30S ribosomal subunit**. This prevents the attachment of aminoacyl-tRNA to the mRNA-ribosome complex, thereby halting bacterial protein synthesis. They are generally bacteriostatic. #### 2. Analysis of Other Options * **Option A (Chloramphenicol):** This is a true statement. Chloramphenicol binds to the **50S ribosomal subunit** and inhibits the enzyme **peptidyl transferase**, preventing peptide bond formation. * **Option C (Metronidazole):** This is a true statement. Metronidazole is a prodrug activated by anaerobic bacteria (via the pyruvate:ferredoxin oxidoreductase system). Its reduced metabolites create reactive intermediates that cause **DNA strand breakage** and helix destabilization. * **Option D (Penicillin):** This is a true statement. Penicillins are Beta-lactams that bind to **Penicillin-Binding Proteins (PBPs)**, inhibiting the cross-linking of peptidoglycan chains (transpeptidation), leading to bacterial cell lysis. #### 3. NEET-PG High-Yield Clinical Pearls * **Mnemonic for Protein Synthesis Inhibitors:** **"Buy AT 30, CELL at 50"** * **30S inhibitors:** **A**minoglycosides (Bactericidal), **T**etracyclines (Bacteriostatic). * **50S inhibitors:** **C**hloramphenicol, **E**rythromycin (Macrolides), **L**inezolid, **L**incosamides (Clindamycin). * **Tetracycline Side Effects:** Fanconi syndrome (expired tetracyclines), tooth discoloration, and photosensitivity. * **Chloramphenicol Toxicity:** Gray Baby Syndrome (due to deficient glucuronidation) and Bone Marrow Suppression (Aplastic Anemia).

Question 462: What is the recommended treatment regimen for chronic Hepatitis B virus (HBV) infection, considering the following options?

A. Interferon
B. Adefovir dipivoxil
C. Lamivudine (Correct Answer)
D. Ganciclovir

Explanation: **Explanation:** **Correct Option: C (Lamivudine)** Lamivudine is a nucleoside analog that inhibits the HBV DNA polymerase (reverse transcriptase). It was the first oral antiviral approved for chronic Hepatitis B. In the context of standard medical examinations like NEET-PG, Lamivudine is frequently cited as a primary treatment for HBV because it effectively suppresses viral replication, reduces hepatic inflammation, and is generally well-tolerated. While newer agents like Tenofovir and Entecavir are now preferred in clinical practice due to lower resistance rates, Lamivudine remains a classic "textbook" answer for HBV pharmacology. **Analysis of Incorrect Options:** * **A. Interferon:** While used in selected cases (especially HBeAg-positive patients with high ALT), it is administered via injection and carries a significant side-effect profile (flu-like symptoms, depression, bone marrow suppression), making it less ideal than oral analogs for many patients. * **B. Adefovir dipivoxil:** This is a nucleotide analog used for HBV, but it is less potent than Lamivudine and carries a risk of nephrotoxicity at higher doses. It is typically reserved for patients with Lamivudine resistance. * **D. Ganciclovir:** This is the drug of choice for **Cytomegalovirus (CMV)** infections. It has no significant clinical role in the treatment of Hepatitis B. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Lamivudine requires intracellular phosphorylation to its active triphosphate form to compete with deoxycytidine triphosphate. * **Resistance:** The major drawback of Lamivudine is the development of resistance due to mutations in the **YMDD motif** of the HBV DNA polymerase. * **Drug of Choice (Current):** For most patients today, **Tenofovir** or **Entecavir** are preferred over Lamivudine due to a higher barrier to resistance. * **HIV Co-infection:** Lamivudine is also a component of ART for HIV; if used for HBV in a co-infected patient, it must be part of a full HAART regimen to prevent HIV resistance.

Question 463: Which of the following are bactericidal inhibitors of protein synthesis?

A. Tetracyclines
B. Aminoglycosides (Correct Answer)
C. Macrolides
D. Lincosamides

Explanation: ### Explanation The fundamental rule in pharmacology is that most protein synthesis inhibitors are **bacteriostatic**, meaning they inhibit growth rather than killing the bacteria directly. **Aminoglycosides** are the notable exception to this rule. **1. Why Aminoglycosides are the Correct Answer:** Aminoglycosides (e.g., Gentamicin, Amikacin, Streptomycin) bind irreversibly to the **30S ribosomal subunit**. Their bactericidal action is unique and multifactorial: * They cause **misreading of mRNA**, leading to the synthesis of "nonsense proteins." * These abnormal proteins are inserted into the bacterial cell membrane, causing increased permeability and leakage. * They also cause total inhibition of the initiation complex of protein synthesis. This irreversible binding and subsequent membrane damage result in rapid bacterial cell death. **2. Why the Other Options are Incorrect:** * **Tetracyclines (A):** These bind reversibly to the 30S subunit. They prevent the attachment of aminoacyl-tRNA to the A-site, but their action is **bacteriostatic**. * **Macrolides (C) & Lincosamides (D):** Both (e.g., Erythromycin, Clindamycin) bind to the **50S ribosomal subunit** and inhibit translocation. They are typically **bacteriostatic**, though they may show bactericidal activity against specific highly sensitive organisms at high concentrations. **3. High-Yield NEET-PG Pearls:** * **Mnemonic for 30S vs 50S:** "**Buy AT 30, CELL at 50**" (**A**minoglycosides, **T**etracyclines bind 30S; **C**hloramphenicol, **E**rythromycin/Macrolides, **L**incosamides, **L**inezolid bind 50S). * **Post-Antibiotic Effect (PAE):** Aminoglycosides exhibit a significant PAE, allowing for once-daily dosing despite a short half-life. * **Synergy:** They are often combined with Cell Wall Inhibitors (like Penicillins) because the wall damage facilitates aminoglycoside entry into the cell. * **Resistance:** The most common mechanism of resistance to aminoglycosides is the production of **bacterial inactivating enzymes** (transferases).

Question 464: Thalidomide is used in all of the following conditions EXCEPT:

A. Erythema nodosum leprosum
B. HIV neuropathy (Correct Answer)
C. HIV associated ulcer
D. Multiple myeloma

Explanation: **Explanation:** Thalidomide is an immunomodulatory agent known for its anti-inflammatory and anti-angiogenic properties. The correct answer is **HIV neuropathy** because Thalidomide is actually **contraindicated** in this condition. One of the most significant and dose-limiting side effects of Thalidomide is **peripheral neuropathy** (sensory and symmetrical). Administering it to a patient already suffering from HIV-associated neuropathy would severely exacerbate nerve damage. **Analysis of Options:** * **Erythema Nodosum Leprosum (ENL):** Thalidomide is the drug of choice for Type 2 lepra reactions (ENL). It acts by inhibiting Tumor Necrosis Factor-alpha (TNF-α), which is the primary mediator in this inflammatory state. * **HIV-associated Ulcers:** Thalidomide is highly effective in treating refractory aphthous ulcers in HIV patients due to its potent anti-inflammatory effects. * **Multiple Myeloma:** It is a standard treatment for Multiple Myeloma. Its anti-angiogenic properties (inhibiting VEGF and bFGF) and its ability to induce apoptosis in malignant plasma cells make it a cornerstone of therapy, often used in combination with dexamethasone. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Inhibits TNF-α and angiogenesis. * **Teratogenicity:** It is a notorious human teratogen causing **Phocomelia** (seal-like limbs). It must never be given during pregnancy (Category X). * **Regulatory:** Its use is strictly controlled through programs like STEPS to prevent fetal exposure. * **Other Uses:** It is also used in Behçet’s disease and certain graft-versus-host diseases.

Question 465: Which of the following statements about sulfonamides is FALSE?

A. Sulfonamides inhibit bacterial dihydropteroate synthase (Correct Answer)
B. Dysfunction of the basal ganglia may occur in the newborn if sulfonamides are administered late in pregnancy
C. Sulfonamide crystalluria is most likely to occur at low urinary pH
D. Sulfonamides are antimetabolites

Explanation: **Explanation:** The question asks for the **FALSE** statement. However, based on pharmacological facts, **Option A is actually a TRUE statement**, making the question likely a "negative-style" query where the options need careful scrutiny. In standard pharmacology, sulfonamides are indeed inhibitors of dihydropteroate synthase. 1. **Mechanism of Action (Options A & D):** Sulfonamides are structural analogs of **Para-Aminobenzoic Acid (PABA)**. They act as **antimetabolites** (Option D is True) by competitively inhibiting the enzyme **dihydropteroate synthase** (Option A is True). This prevents the synthesis of dihydrofolic acid, ultimately inhibiting bacterial DNA synthesis. 2. **Kernicterus (Option B):** This is a **TRUE** statement. Sulfonamides compete with bilirubin for binding sites on serum albumin. In newborns (especially if given late in pregnancy), this increases free bilirubin levels, which can cross the blood-brain barrier and deposit in the **basal ganglia**, leading to **Kernicterus**. 3. **Crystalluria (Option C):** This is a **TRUE** statement. Sulfonamides and their acetylated metabolites are poorly soluble in **acidic urine**. This can lead to the formation of crystals (crystalluria), potentially causing renal damage. Alkalinization of urine and high fluid intake are used to prevent this. **Note on the Question:** Since all options (A, B, C, and D) are scientifically accurate descriptions of sulfonamides, this question may contain a typographical error in the "Correct Answer" key provided. In a standard exam, you must identify the statement that contradicts established pharmacology. **NEET-PG High-Yield Pearls:** * **Resistance:** Occurs via increased PABA production or mutation in dihydropteroate synthase. * **Drug of Choice:** Sulfadiazine + Pyrimethamine is the treatment for **Toxoplasmosis**. * **Adverse Effects:** Stevens-Johnson Syndrome (SJS), G6PD-induced hemolysis, and Kernicterus in neonates. * **Mnemonic:** Sulfonamides inhibit **S**ynthase; Trimethoprim inhibits **R**eductase (Dihydrofolate reductase).

Question 466: Cobicistat is used along with which of the following antiretroviral drugs?

A. Indinavir
B. Darunavir (Correct Answer)
C. Ritonavir
D. Saquinavir

Explanation: **Cobicistat** is a potent inhibitor of the cytochrome P450 enzyme **CYP3A4**. It does not possess any intrinsic antiviral activity; instead, it acts as a **pharmacokinetic enhancer** (a "booster"). By inhibiting the metabolism of co-administered drugs, it increases their plasma concentrations, allowing for lower doses and improved patient compliance [1]. 1. **Why Darunavir is correct:** Darunavir is a Protease Inhibitor (PI) that is extensively metabolized by CYP3A4. To achieve therapeutic levels, it must be "boosted." Cobicistat is FDA-approved for use with **Darunavir** (and Atazanavir) to enhance its efficacy. This combination is frequently used in fixed-dose combinations (e.g., Prezcobix) [1]. 2. **Why other options are incorrect:** * **Ritonavir:** This is itself a potent CYP3A4 inhibitor and the original "booster" drug. It is used to boost other PIs, but it is not boosted by Cobicistat [1]. * **Indinavir and Saquinavir:** These are older Protease Inhibitors. While they can be boosted by Ritonavir, they are rarely used in modern clinical practice and are not the standard partners for Cobicistat in current therapeutic guidelines [1]. **Clinical Pearls for NEET-PG:** * **Cobicistat vs. Ritonavir:** Unlike Ritonavir, Cobicistat has **no induction effect** on other enzymes and lacks antiviral activity, leading to fewer drug-drug interactions and side effects. * **Renal Caution:** Cobicistat can cause a functional (but harmless) increase in **serum creatinine** by inhibiting tubular secretion without affecting actual GFR. * **Elvitegravir:** Cobicistat is also a key component of the "Stribild" and "Genvoya" regimens, where it boosts the Integrase Inhibitor Elvitegravir.

Question 467: Which of the following drugs acts by inhibiting DNA-dependent RNA synthesis in mycobacteria?

A. Ciprofloxacin
B. Isoniazid (INH)
C. Rifampicin (Correct Answer)
D. Ethambutol

Explanation: ### Explanation **Correct Answer: C. Rifampicin** **Mechanism of Action:** Rifampicin is a bactericidal antitubercular drug that acts by inhibiting **DNA-dependent RNA polymerase**. It binds to the $\beta$-subunit of this enzyme, preventing the initiation of mRNA synthesis (transcription). Since mycobacteria cannot produce essential proteins without mRNA, their growth is arrested, leading to cell death. **Analysis of Incorrect Options:** * **A. Ciprofloxacin:** This is a fluoroquinolone that inhibits **DNA Gyrase** (Topoisomerase II) and Topoisomerase IV, thereby interfering with DNA replication and repair, not RNA synthesis. * **B. Isoniazid (INH):** This prodrug is activated by the enzyme *KatG*. It inhibits the synthesis of **mycolic acids** (by targeting the InhA enzyme), which are essential components of the mycobacterial cell wall. * **D. Ethambutol:** This is a bacteriostatic drug that inhibits **Arabinosyl transferase**, an enzyme required for the synthesis of arabinogalactan in the mycobacterial cell wall. **NEET-PG High-Yield Pearls:** * **Resistance:** Resistance to Rifampicin occurs due to mutations in the **rpoB gene** (which codes for the $\beta$-subunit of RNA polymerase). * **Side Effects:** A classic "exam favorite" side effect is the **orange-red discoloration** of body fluids (urine, sweat, tears, saliva). It is also a potent **Cytochrome P450 inducer**, leading to numerous drug-drug interactions (e.g., reducing the efficacy of oral contraceptives and warfarin). * **Clinical Use:** Apart from TB, it is used in Leprosy (as part of MDT) and as prophylaxis for Meningococcal and *H. influenzae* meningitis.

Question 468: Oseltamivir acts by inhibiting which viral enzyme?

A. Neuraminidase (Correct Answer)
B. Dismutase
C. Lyase
D. Endonuclease

Explanation: **Explanation:** **Mechanism of Action (The Correct Answer):** Oseltamivir (Tamiflu) is a potent and selective inhibitor of **Neuraminidase**, an enzyme found on the surface of Influenza A and B viruses [1]. Under normal conditions, neuraminidase cleaves sialic acid residues on the host cell surface, allowing newly formed viral particles to be released from the infected cell to infect neighboring cells. By inhibiting this enzyme, Oseltamivir causes the viral progeny to clump together at the cell surface, effectively halting the spread of infection within the respiratory tract. **Analysis of Incorrect Options:** * **Dismutase (B):** Superoxide dismutase is an antioxidant enzyme that neutralizes free radicals; it is not a target for antiviral therapy. * **Lyase (C):** Lyases are a general class of enzymes that catalyze the breaking of chemical bonds; they are not specific targets for anti-influenza drugs. * **Endonuclease (D):** While **Baloxavir marboxil** (a newer anti-influenza drug) inhibits the cap-dependent endonuclease, Oseltamivir does not. **High-Yield Clinical Pearls for NEET-PG:** * **Spectrum:** Effective against both **Influenza A and B** (including H1N1) [1]. * **Administration:** It is an **oral prodrug** (converted to oseltamivir carboxylate in the liver) [2]. In contrast, **Zanamivir** is administered via inhalation. * **Timing:** For maximum efficacy, it must be started within **48 hours** of symptom onset [2]. * **Side Effects:** Most common are nausea and vomiting [3]; rare neuropsychiatric events (confusion, self-injury) have been reported in pediatric patients.

Question 469: An inhibitor of bacterial protein synthesis with a narrow spectrum of antibacterial activity has been used in the management of abdominal abscess caused by Bacteroides fragilis, though antibiotic-associated colitis has occurred. Which of the following drugs is being described?

A. Clarithromycin
B. Clindamycin (Correct Answer)
C. Minocycline
D. Ticarcillin

Explanation: ### Explanation The correct answer is **Clindamycin**. **1. Why Clindamycin is correct:** Clindamycin is a **Lincosamide** antibiotic that inhibits bacterial protein synthesis by binding to the **50S ribosomal subunit**. It has a relatively narrow spectrum, primarily targeting **Gram-positive cocci** (including MRSA) and **anaerobes**. It is the drug of choice for anaerobic infections above the diaphragm, but it is also highly effective against abdominal anaerobes like ***Bacteroides fragilis***. A classic, high-yield adverse effect of Clindamycin is **Antibiotic-Associated Pseudomembranous Colitis**, caused by the overgrowth of *Clostridioides difficile* due to the suppression of normal gut flora. **2. Why the other options are incorrect:** * **Clarithromycin:** A Macrolide used primarily for respiratory tract infections (*H. influenzae*, *M. pneumoniae*) and *H. pylori* eradication. It does not have significant activity against *B. fragilis*. * **Minocycline:** A Tetracycline used for acne or MRSA. While it inhibits protein synthesis (30S subunit), it is not the preferred agent for deep-seated anaerobic abscesses and is less commonly associated with *C. difficile* than Clindamycin. * **Ticarcillin:** An antipseudomonal penicillin. It inhibits **cell wall synthesis** (not protein synthesis) and has a broad spectrum of activity. **3. NEET-PG High-Yield Pearls:** * **Mechanism:** Same as Macrolides and Chloramphenicol (50S inhibition). * **Clinical Rule:** "Anaerobes above the diaphragm = Clindamycin; Anaerobes below the diaphragm = Metronidazole" (though Clindamycin is active against both). * **C. difficile Treatment:** If Clindamycin causes colitis, the treatment of choice is **Oral Vancomycin** or **Fidaxomicin** (Metronidazole is now second-line). * **Resistance:** Cross-resistance occurs between Macrolides and Clindamycin via **MLSB resistance** (methylation of the 23S rRNA).

Question 470: Which of the following is not an indication for cotrimoxazole?

A. Lower urinary tract infection (UTI)
B. Prostatitis
C. Chancroid (Correct Answer)
D. Typhoid fever

Explanation: **Explanation:** Cotrimoxazole is a fixed-dose combination of **Sulfamethoxazole** and **Trimethoprim** (5:1 ratio) that acts via sequential blockade of folate synthesis. While it was once a broad-spectrum mainstay, increasing resistance has altered its clinical utility. **Why Chancroid is the correct answer:** Chancroid is caused by *Haemophilus ducreyi*. According to current CDC and WHO guidelines, the first-line treatment for Chancroid is **Azithromycin (1g orally, single dose)** or **Ceftriaxone (250mg IM)**. Cotrimoxazole is no longer recommended for Chancroid due to widespread resistance and the availability of more effective single-dose regimens. **Analysis of Incorrect Options:** * **Lower UTI:** Cotrimoxazole remains an effective option for uncomplicated UTIs caused by sensitive strains of *E. coli*, though it is often reserved for cases where first-line agents like Nitrofurantoin are contraindicated. * **Prostatitis:** Trimethoprim is highly lipid-soluble and achieves excellent penetration into prostatic fluid, making cotrimoxazole a valid choice for bacterial prostatitis. * **Typhoid Fever:** Although Fluoroquinolones and Ceftriaxone are now preferred due to MDR (Multi-Drug Resistant) *Salmonella typhi*, cotrimoxazole is still considered an alternative indication in sensitive cases. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Cotrimoxazole is the DOC for ***Pneumocystis jirovecii* pneumonia** (both prophylaxis and treatment) and ***Nocardiosis***. * **Adverse Effects:** Watch for **Stevens-Johnson Syndrome (SJS)**, crystalluria (sulfonamide component), and megaloblastic anemia (trimethoprim component). * **Contraindication:** Avoid in pregnancy (folate antagonism) and in patients with G6PD deficiency (risk of hemolysis).

Practice by Chapter

Beta-Lactam Antibiotics

Practice Questions

Aminoglycosides

Practice Questions

Macrolides and Ketolides

Practice Questions

Tetracyclines

Practice Questions

Quinolones

Practice Questions

Sulfonamides and Trimethoprim

Practice Questions

Antimycobacterial Drugs

Practice Questions

Antifungal Agents

Practice Questions

Antiviral Drugs

Practice Questions

Antiparasitic Agents

Practice Questions

Principles of Antimicrobial Selection

Practice Questions

Antimicrobial Resistance

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free